Your browser doesn't support javascript.
loading
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman, Robin; Alzouebi, Mymoona; Beesley, Sharon; Birtle, Alison J; Brock, Susannah; Cathomas, Richard; Chakraborti, Prabir; Chowdhury, Simon; Cook, Audrey; Elliott, Tony; Gale, Joanna; Gibbs, Stephanie; Graham, John D; Hetherington, John; Hughes, Robert; Laing, Robert; McKinna, Fiona; McLaren, Duncan B; O'Sullivan, Joe M; Parikh, Omi; Peedell, Clive; Protheroe, Andrew; Robinson, Angus J; Srihari, Narayanan; Srinivasan, Rajaguru; Staffurth, John; Sundar, Santhanam; Tolan, Shaun; Tsang, David; Wagstaff, John; Parmar, Mahesh K B.
Afiliación
  • James ND; Warwick Medical School, University of Warwick, Coventry, UK; University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK.
  • Sydes MR; MRC Clinical Trials Unit at UCL, London, UK. Electronic address: m.sydes@ucl.ac.uk.
  • Clarke NW; Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK.
  • Mason MD; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
  • Dearnaley DP; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
  • Spears MR; MRC Clinical Trials Unit at UCL, London, UK.
  • Ritchie AW; MRC Clinical Trials Unit at UCL, London, UK.
  • Parker CC; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
  • Russell JM; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Attard G; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
  • de Bono J; The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK.
  • Cross W; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds.
  • Jones RJ; Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Thalmann G; Department of Urology, University Hospital, Bern, Switzerland.
  • Amos C; MRC Clinical Trials Unit at UCL, London, UK.
  • Matheson D; Patient rep, MRC Clinical Trials Unit at UCL, London, UK.
  • Millman R; Patient rep, MRC Clinical Trials Unit at UCL, London, UK.
  • Alzouebi M; Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK.
  • Beesley S; Kent Oncology Centre, Maidstone Hospital, Maidstone, UK.
  • Birtle AJ; Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK.
  • Brock S; Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland.
  • Cathomas R; Kantonsspital Graubünden, Chur, Switzerland.
  • Chakraborti P; Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK.
  • Chowdhury S; Department of Medical Oncology, Guy's Hospital, London, UK.
  • Cook A; Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK.
  • Elliott T; Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Gale J; Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK.
  • Gibbs S; Department of Oncology, Queen's Hospital, Romford, UK.
  • Graham JD; Beacon Centre, Musgrove Park Hospital, Taunton, UK.
  • Hetherington J; Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK.
  • Hughes R; Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK.
  • Laing R; Department of Oncology, Royal Surrey County Hospital, Guildford, UK.
  • McKinna F; Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK.
  • McLaren DB; Department of Oncology, Western General Hospital, Edinburgh, UK.
  • O'Sullivan JM; Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK.
  • Parikh O; Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK.
  • Peedell C; Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK.
  • Protheroe A; Department of Oncology, Churchill Hospital, Oxford, UK.
  • Robinson AJ; Department of Oncology, Sussex Cancer Centre, Brighton, UK.
  • Srihari N; Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK.
  • Srinivasan R; Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK.
  • Staffurth J; Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK.
  • Sundar S; Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK.
  • Tolan S; Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK.
  • Tsang D; Department of Oncology, Southend & Basildon Hospitals, Essex, UK.
  • Wagstaff J; The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK.
  • Parmar MK; MRC Clinical Trials Unit at UCL, London, UK.
Lancet ; 387(10024): 1163-77, 2016 Mar 19.
Article en En | MEDLINE | ID: mdl-26719232
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Hormonales / Taxoides / Difosfonatos / Imidazoles / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Antineoplásicos Hormonales / Taxoides / Difosfonatos / Imidazoles / Antagonistas de Andrógenos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Lancet Año: 2016 Tipo del documento: Article País de afiliación: Reino Unido